MX2021012272A - Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. - Google Patents

Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.

Info

Publication number
MX2021012272A
MX2021012272A MX2021012272A MX2021012272A MX2021012272A MX 2021012272 A MX2021012272 A MX 2021012272A MX 2021012272 A MX2021012272 A MX 2021012272A MX 2021012272 A MX2021012272 A MX 2021012272A MX 2021012272 A MX2021012272 A MX 2021012272A
Authority
MX
Mexico
Prior art keywords
cells
compositions
methods
immunomodulatory
monocytes
Prior art date
Application number
MX2021012272A
Other languages
English (en)
Inventor
Douglas C Hooper
David W Andrews
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of MX2021012272A publication Critical patent/MX2021012272A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación provee composiciones farmacéuticas que comprenden ácidos nucleicos capaces de hacer blanco en la expresión de IGF-1R en las células M2; la presente divulgación también provee métodos para la reducción selectiva de células M2 haciendo blanco en la expresión de IGF-1R en estas células; la presente divulgación provee, además, métodos para el tratamiento del cáncer y mejoramiento terapéutico haciendo blanco en la expresión de IGF-1R en células M2 en los pacientes; la composición farmacéutica de la presente invención es eficaz cuando se le administra sistémicamente a los sujetos que la necesitan; la facilidad de administración de la composición farmacéutica facilita el tratamiento y mejora el cumplimiento del paciente.
MX2021012272A 2015-04-10 2017-10-09 Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. MX2021012272A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562145758P 2015-04-10 2015-04-10

Publications (1)

Publication Number Publication Date
MX2021012272A true MX2021012272A (es) 2021-11-12

Family

ID=57072956

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012982A MX2017012982A (es) 2015-04-10 2016-04-11 Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
MX2021012272A MX2021012272A (es) 2015-04-10 2017-10-09 Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017012982A MX2017012982A (es) 2015-04-10 2016-04-11 Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.

Country Status (8)

Country Link
US (5) US10206942B2 (es)
EP (1) EP3280806A4 (es)
JP (3) JP6957035B2 (es)
CN (1) CN108260357A (es)
AU (2) AU2016246134B2 (es)
CA (1) CA2982205A1 (es)
MX (2) MX2017012982A (es)
WO (1) WO2016164916A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108260357A (zh) 2015-04-10 2018-07-06 托马斯杰弗逊大学 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物
MX2019003070A (es) 2016-09-16 2019-10-14 Bio Path Holdings Inc Terapia de combinacion con oligonucleotidos antisentido liposomales.
WO2018156725A1 (en) * 2017-02-24 2018-08-30 Thomas Jefferson University Methods and compositions for inhibiting tumor growth and enhancing immune responses to tumors
NZ756820A (en) * 2017-03-09 2022-08-26 Univ Jefferson Methods and compositions for treating cancers using antisense
WO2018195281A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
US20210115451A1 (en) * 2017-04-19 2021-04-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
EP3651780A4 (en) * 2017-07-14 2021-04-07 Minzhen Xu METHOD FOR INDUCING M1-DOMINATED IMMUNE RESPONSE AND PHARMACEUTICAL COMPOSITIONS
GB201714330D0 (en) * 2017-09-06 2017-10-18 Järver Peter Oligonucleotides
US20210052875A1 (en) * 2018-01-24 2021-02-25 Thomas Jefferson University Biodiffusion chamber
MX2021005168A (es) * 2018-11-02 2021-08-24 Univ Jefferson Metodos y composiciones para el tratamiento de cancer de mama usando antisentido.
CA3118424A1 (en) * 2018-11-02 2020-05-07 Thomas Jefferson University Methods and compositions for treating hepatocellular carcinoma using antisense

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK114394B (da) 1963-06-17 1969-06-23 O Hoyer Fremgangsmåde ved emballering af aflange formlegemer, navnlig ispinde, samt maskine til udøvelse af fremgangsmåden.
US3331526A (en) 1964-07-20 1967-07-18 Levenson Leonard Lionel Ultrahigh vacuum seal
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
JPH08508405A (ja) * 1993-03-26 1996-09-10 トーマス ジェファーソン ユニバーシティ Ｉｇｆ−１レセプターアンチセンスオリゴヌクレオチドにより細胞の増殖を阻害し、且つ細胞を分化させる方法
US5714170A (en) * 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
US6541036B1 (en) 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
CA2339858A1 (en) * 1998-08-13 2000-02-24 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor
US6144553A (en) 1998-09-09 2000-11-07 Sun Microsystems, Inc. Refrigeration cooled disk storage assembly
US7846906B2 (en) 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
CA2447400A1 (en) 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
CN102898426B (zh) * 2012-11-15 2015-04-22 江苏先声药业有限公司 抑制igf-1r酪氨酸激酶活性的吡啶并吡唑类衍生物
CN108260357A (zh) 2015-04-10 2018-07-06 托马斯杰弗逊大学 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物
NZ756820A (en) 2017-03-09 2022-08-26 Univ Jefferson Methods and compositions for treating cancers using antisense

Also Published As

Publication number Publication date
WO2016164916A1 (en) 2016-10-13
JP2018515598A (ja) 2018-06-14
JP2021193143A (ja) 2021-12-23
AU2016246134B2 (en) 2022-04-21
US10206942B2 (en) 2019-02-19
AU2016246134A1 (en) 2017-11-02
JP6957035B2 (ja) 2021-11-02
US10265339B2 (en) 2019-04-23
US20180271894A1 (en) 2018-09-27
US20220072025A1 (en) 2022-03-10
CN108260357A (zh) 2018-07-06
US20180235996A1 (en) 2018-08-23
US11077133B2 (en) 2021-08-03
MX2017012982A (es) 2018-07-06
US20170056430A1 (en) 2017-03-02
US10543226B2 (en) 2020-01-28
EP3280806A4 (en) 2018-12-05
AU2022206776A1 (en) 2022-09-15
JP7428397B2 (ja) 2024-02-06
JP2024028529A (ja) 2024-03-04
EP3280806A1 (en) 2018-02-14
US20200197435A1 (en) 2020-06-25
CA2982205A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
MX2021012272A (es) Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2019010601A (es) Terapia de combinacion para tratar cancer.
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MY188139A (en) Sodium channel modulators for the treatment of pain
MX2022015748A (es) Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MX2017013142A (es) Terapia combinada para tratar cáncer.
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
WO2016025635A3 (en) Combination therapy for treating cancer
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
EA201591925A1 (ru) Терапевтические композиции и их применение
WO2016043874A3 (en) Combination therapy for treating cancer
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
EA202091908A3 (ru) Комбинированная терапия для лечения онкологического заболевания